| General Information | |
|---|---|
| ZINC ID | ZINC000013611873 |
| Molecular Weight (Da) | 466 |
| SMILES | Cc1c(C(=O)NN2CCOCC2)nc(-c2ccc(Cl)cc2Cl)n1-c1ccc(Cl)cc1 |
| Molecular Formula | C21Cl3N4O2 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 117.454 |
| HBA | 4 |
| HBD | 1 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 30 |
| LogP | 4.958 |
| Activity (Ki) in nM | 31.6228 |
| Polar Surface Area (PSA) | 59.39 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.805 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 17 |
| Fraction csp3 | 0.24 |
| Ilogp | 4.08 |
| Xlogp3 | 5.09 |
| Wlogp | 4.4 |
| Mlogp | 3.92 |
| Silicos-it log p | 4.43 |
| Consensus log p | 4.38 |
| Esol log s | -6.02 |
| Esol solubility (mg/ml) | 0.000441 |
| Esol solubility (mol/l) | 0.00000094 |
| Esol class | Poorly sol |
| Ali log s | -6.08 |
| Ali solubility (mg/ml) | 0.000387 |
| Ali solubility (mol/l) | 0.00000083 |
| Ali class | Poorly sol |
| Silicos-it logsw | -7.72 |
| Silicos-it solubility (mg/ml) | 0.00000877 |
| Silicos-it solubility (mol/l) | 1.88E-08 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.53 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.41 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.319 |
| Logd | 4.032 |
| Logp | 4.293 |
| F (20%) | 0.001 |
| F (30%) | 0.003 |
| Mdck | - |
| Ppb | 98.81% |
| Vdss | 0.315 |
| Fu | 1.19% |
| Cyp1a2-inh | 0.307 |
| Cyp1a2-sub | 0.701 |
| Cyp2c19-inh | 0.877 |
| Cyp2c19-sub | 0.79 |
| Cl | 3.809 |
| T12 | 0.062 |
| H-ht | 0.545 |
| Dili | 0.934 |
| Roa | 0.547 |
| Fdamdd | 0.51 |
| Skinsen | 0.035 |
| Ec | 0.003 |
| Ei | 0.012 |
| Respiratory | 0.441 |
| Bcf | 2.029 |
| Igc50 | 4.124 |
| Lc50 | 5.42 |
| Lc50dm | 6.044 |
| Nr-ar | 0.015 |
| Nr-ar-lbd | 0.01 |
| Nr-ahr | 0.895 |
| Nr-aromatase | 0.901 |
| Nr-er | 0.687 |
| Nr-er-lbd | 0.019 |
| Nr-ppar-gamma | 0.064 |
| Sr-are | 0.899 |
| Sr-atad5 | 0.215 |
| Sr-hse | 0.07 |
| Sr-mmp | 0.742 |
| Sr-p53 | 0.903 |
| Vol | 421.019 |
| Dense | 1.102 |
| Flex | 0.208 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 2 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 1 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.602 |
| Synth | 2.515 |
| Fsp3 | 0.238 |
| Mce-18 | 53.077 |
| Natural product-likeness | -1.517 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |